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Wnt signalingimportance: (1)
4
 Is an ancient and evolutionarily conserved pathway that
regulates crucial aspects of:
 Cell fate determination.
 Cell migration.
 Organogenesis during embryonic development.
 ….
9 January 2017
5Wnt signaling pathways:
Including : (2)
1) The canonical or Wnt/β-catenin dependent pathway
2) The non-canonical or β-catenin-independent pathway
which can be divided into the:
 Planar Cell Polarity pathway
 the Wnt/Ca2+ pathway
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Wnt Signaling  Pathway
Canonical
Non-canonical
B,catenin
Ca 2+ PCP
• Osteoblast cell proliferation
•Cell fate determination
•General bone maintenance
•Body axis specification
•Cancer
• intracellular Ca2+ 
conc. Activation of JNK
Affect cytoskeletal organisation
6
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8 Wnt inhibitory factor-1 , a secreted protein that binds to Wnt
proteins and inhibits their activities. (3)
 WIF1 are potentially important in cancers as Wnt pathway
inhibitors and increased apoptosis. (4)
12q14.3
WIF1
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9WIF1
 This protein contains a WNT inhibitory factor (WIF) domain and 5
epidermal growth factor (EGF)-like domains. (5)
.
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WT1
 11p13
 7490 bp
WT1 could be the role of the tumor suppressor or Oncogene. (6)
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 WT1 encodes a zinc-finger transcription factor expressed in
kidney, gonads, spleen, and mesothelium. (7)
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Defining Epigenetics 
13
 Reversible changes in gene 
expression/function without 
changes in DNA sequence.
 Can be inherited from 
precursor cells. (8)
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DNA methylation
14
 is an epigenetic marks associated with transcriptional regulation
and genome structure. (9)
 Epigenetic changes in signaling pathway:
Wnt / B.catenin could be an attractive strategy for cancer therapy is
dependent on the Wnt. (10)
15
 Methylation considered as a control mechanism of the gene profile  
while the activity of oncogenes cause development of tumor. 
 Tumor suppressor factors play an important role in controlling and 
changing the genetic profile of terminally differentiated cells. (11)
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What does DNA methylation do?
16
Global Methylation Regional Methylation
Low denisity
Genomic stability
Repression of transposable elements
High Density – CpG Islands (CGIs)
Located in promoters and introns
G ne Sile cing
Promoter Gene
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DNA Hypomethylation activate oncogenes 
And  initiate chromosome instability, 
DNA Hypermethylation silencing of tumor suppressor genes. 
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Wif1 antagonist of the Wnt pathway and is a Tumor suppressor.
(Epigenetic mechanisms in some tumors have been shown to
cause inactivation of these genes.) (12)
Tumor suppressor gene hypermethylation CPG areas in many cases
have been reported in human cancer. ( including colorectal cancer) . (13)
 Decrease the Wnt pathway activity.
 Decrease cell growth.
 Increase cell apoptosis. (14)
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 is targeted for epigenetic silencing in human breast cancer. (15)
Wif1 methylation is a prognostic marker for cancer of the mouth.
(16)
wif1
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• Wif1 gene in cancers of the prostate and breast, lung and bladder
was down regulated. (9)
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 Jaroslaw.et all ; 2015
Analyze methylation of Wif1 in 16 OSCC cell line and 43 tumor
section from primary OC patient, frequently methylation was shown.
(9)
 Shanghui.et all ; 2015
Analyzed Wif1-expression level by IHC staining and semi-quantitative
RT-PCR was shown, Wif1 in normal oral mucous tissue was
expressed, and in OSCC with progression of disease, expression has
been decreased. (17)
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 Ramachandran et al., 2011:
WIF1 is downregulated by promoter hypermethylation in 87.5% of
primary cervical cancer. (18)
 Lambiv et al., 2011:
WIF1 re-expression abolishes tumorigenicity of glioblastoma cell lines
potentially by inducing senescence. (19)
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 Rubin et al., 2010:
Hypermethylation of the WIF1 promoter is found in the majority of
osteosarcoma cell lines tested and it correlates with WIF1 mRNA
down regulation. (20)
 Deng et al., 2010:
WIF1 is frequently down regulated through promoter
hypermethylation in HCC . (21)
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 Kawakami et al., 2009:
WIF1 is downregulated by promoter hypermethylation and when re-
expressed induces apoptosis in Renal cell carcinoma (RCC )cells. (22)
 Bladder cancer ( Tang et al., 2009. 23 )
 Breast cancer ( Ai et al., 2006. 24 )
 Gastrointestinal cancers ( Taniguchi et al., 2005. 25 )
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 Reduction in regulatory of WIF1 examined in many malignant
tumors such as:
 Hepatocellular carcinoma Cancers . (26)
 Nasopharynx carcinoma Cancers . (27) 
 Lung cancer.  (28)  
 Clone Cancers.  (29) 
 Esophageal adenocarcinoma Cancers . (30) 
 Melanoma Cancers.  (31) 
 Bladder Cancers . (32)
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 Decreased WIF1 expression , correlated with methylation of CpG
dinucleotides within the WIF1 promoter. (33)
 Hypermethylation of WIF1 gene promoter and low expression,
activate Wnt signaling aberrantly and induce the development of
various human tumors. (34)
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Normal biological functions Development of 
genitourinary system
Development of kidney
Adult kidney
Heart development
Neuron development
WT1
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 The Wilms’ tumor 1 (WT1) gene encodes a transcription factor
important for normal cellular development and cell survival. (35)
 WT1 was initially discovered as a tumor suppressor in Wilms’ tumor
 The N terminus of WT1 is negatively charged and contains a high
concentration of prolin and glutamine residues. (36)
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 Laux DE. et all ;1999
detected aberrantly methylated sites in the ﬁrst intron of the WT1
gene in breast cancer. (37)
 David M. et all ; 2001:
WT1 is overexpressed in the majority of primary breast tumors.
Tumor-specific methylation of the CpG island occurs in breast cancer
but appears to be inconsequential to gene expression. (38)
WT1
9 January 2017
31
 Oji Y.et all; 2003 
In analyzed of HNSCC showed that WT1 was not methylated.  (39)
 Oji Y.et all ;2004    
Overexpression of the WT1 Gene in Esophageal Cancer. (40)
 Kaneuchi M.et all ;2005
examined The WT1 promoter was significantly methylated in clear
cell adenocarcinoma (88.2%) compared with serous
adenocarcinoma (24.0%). (41)
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 Moriya S.et all; 2008
Showed that , in lung SCC ,WT1 expression was down regulated. (42)
 Pierdonato B. et al., 2012
Hypermethylation of WT1 gene could be involved in the
carcinogenesis of NSCLC ( non small cell lung cancer).
 Jitesh PV.et all; 2013  
WT1 gene in ESCC and Non ESCC patient has different methylation
status.
And show that, epigenetic changes Necessary for cancer development. (43)
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MikamiyT.et all; 2013
In analyze of 6 cell line of OSCC with IHC , WT1 was over expressed.
(44)
Shimodaria S.et all; 2016
WT1 over expression was observed in autopsy sample of pancreatic
adenocarcinoma. (45)
OjiY.et all; 2016
In leukemia WT1 have high expression. (46)
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 Methylation of genes as biomarkers for cancer detection model
can be used.
 Furthermore, by recognizing the methylation patterns in cancer
types, it can also be used for treatment.
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